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Abstract
Background: Indacaterol is a novel once-daily ultra long-acting b2-agonist for the treatment of chronic obstructive
pulmonary disease. It is known that b2-agonists, like other adrenergic compounds, can prolong the QT-interval. This
thorough QT/QTc study (as per ICH E14 guideline) evaluated the effect of indacaterol on the QT interval in healthy
subjects.
Methods: In this randomized, double-blind, parallel-group, placebo- and positive-controlled (open-label
moxifloxacin) study, non-smoking healthy subjects (18-55 years, body mass index: 18.5-32.0 kg/m2) were
randomized (4:4:2:4:1) to 14-day treatment with once-daily indacaterol (150 μg, 300 μg, or 600 μg), placebo, or
placebo/moxifloxacin (double-blind 14-day treatment with placebo and a single open-label dose of 400 mg
moxifloxacin on Day 14). The primary endpoint was the change from baseline on Day 14 in QTcF (QT interval
corrected for heart rate using Fridericia’s formula).
Results: In total, 404 subjects were randomized to receive indacaterol (150 [n = 108], 300 [n = 108], 600 μg [n =
54]), placebo (n = 107), or placebo/moxifloxacin (n = 27); 388 subjects completed the study. Maximal time-
matched mean (90% confidence intervals) treatment differences from placebo in QTcF change from baseline on
Day 14 were 2.66 (0.55, 4.77), 2.98 (1.02, 4.93) and 3.34 (0.86, 5.82) ms for indacaterol 150 μg, 300 μg and 600 μg,
respectively. Study sensitivity was confirmed with moxifloxacin demonstrating a significant maximal time-matched
QTcF prolongation of 13.90 (10.58, 17.22) ms compared to placebo. All indacaterol doses were well tolerated.
Conclusion: Indacaterol, at doses up to 600 μg once daily (2-4 times the therapeutic dose) does not have any
clinically relevant effect on the QT interval.
Trial Registration: ClinicalTrials.gov: NCT01263808
Background
Indacaterol is a novel, inhaled, ultra long-acting b2-ago-
nist (LABA) [1] that is approved in a number of coun-
tries, including throughout the European Union (EU), at
doses of 150 and 300 μg once-daily (OD) for the main-
tenance bronchodilator treatment of airflow obstruction
in adult patients with chronic obstructive pulmonary
disease (COPD). It is a partial agonist at the human b2-
adrenoceptor with a binding affinity similar to that of
formoterol, and an intrinsic activity higher than that of
salbutamol and salmeterol [2,3]. The efficacy and safety
of indacaterol in patients with COPD have been pre-
viously evaluated in number of studies, where once-daily
indacaterol has demonstrated 24-h bronchodilation with
a rapid onset of action [4-8].
The current International Conference on Harmonisa-
tion (ICH) of Technical Requirements for Registration of
Pharmaceuticals for Human Use E14 Guidance [9]
recommends that all new non-antiarrhythmic drugs that
are systemically bioavailable should undergo a rigorous
electrocardiographic evaluation as part of a controlled
clinical study (that is a “thorough QT study”), to evaluate
their potential QT liability. An abnormal QT-interval
morphology is considered to be a surrogate biomarker
for the proarrhythmic risk of non-antiarrhythmic drugs.
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Results from a meta-analysis of 33 randomized placebo-
controlled trials (N = 6623) evaluating the arrhythmo-
genic potential of b-agonists [10] suggest that inhaled b2-
agonists have a potential to increase heart rate and the
incidence of ventricular arrhythmias in patients with
obstructive airway disease. It is, therefore, especially
important to conduct a thorough QT study as part of the
development of an inhaled b2-agonist.
A thorough QT study is typically carried out in
healthy volunteers as opposed to individuals at increased
risk of arrhythmias. It is driven by a test of non-inferior-
ity on the rate-corrected QT interval (the QTc interval)
and is considered negative when the largest time-
matched mean difference in the QTc interval between
the study drug and placebo is less than or equal to
(approximately) 5 ms, with the upper bound of the 95%
one-sided confidence interval (CI) excluding 10 ms [9].
The present study, which, to the best of our knowl-
edge, is the largest thorough QT study conducted thus
far with any b2-agonist, was designed primarily to char-
acterize the maximum mean QTc interval prolongation
following treatment with three different doses of indaca-
terol in healthy individuals. Safety and tolerability and
pharmacokinetics of indacaterol were also assessed.
Methods
This was a randomized, multiple-dose, placebo- and
positive-controlled, parallel-group study conducted at a
single clinical research center in the US. The study
design was in compliance with the recommendation of
the ICH E14 guideline [9] for thorough QT studies. The
study was approved by the institutional review board
(Independent Investigational Review Board; Sea View
Research, Inc.) of the participating study center and was
conducted in accordance with the ethical principles
embodied in the Declaration of Helsinki (1989).
Subjects
The study population consisted of healthy, nonsmoking
male and female subjects aged between 18 and 55 years
(inclusive), with a body mass index within the range of
18.5-32.0 kg/m2 and weight ≥50 kg at screening. Indivi-
duals with a history of or current ECG abnormalities
(PR >240 ms; QRS complex >110 ms; QTc interval [Fri-
dericia’s; QTcF] >430 ms for males and >440 ms for
females; or any significant morphological changes other
than nonspecific T-wave changes) were excluded from
the study. In addition, those with serum potassium <3.5
mmol/L or magnesium <0.8 mmol/L; recent blood
donation or blood loss; or a history of diabetes mellitus,
hyperthyroidism, impaired renal function, drug or alco-
hol abuse, or any significant illness within 2 weeks of
dosing were also excluded. All subjects provided written
informed consent prior to taking part in the study.
Study design and treatments
The study comprised a screening period (up to 21 days),
a baseline visit (Day -1), a 14-day randomized treatment
period (Days 1-14), and an end-of-study evaluation at 7
days after the last dose. At the start of the randomized
treatment period, eligible subjects were randomized to
one of the following five treatment groups in a 4:4:2:4:1
ratio: indacaterol 150 and 300 μg (therapeutic doses),
indacaterol 600 μg (supratherapeutic dose), placebo, and
placebo/moxifloxacin. Moxifloxacin, a fluoroquinolone
antimicrobial agent, was used as a positive calibrator to
determine the assay sensitivity in this study. This dose
of 400 mg represents the daily therapeutic dose of moxi-
floxacin, single doses of which have been consistently
associated with an increase in mean QT interval vs pla-
cebo in excess of 5 ms in healthy volunteers [11].
Indacaterol and matching placebo were administered
once daily for 14 days via a single-dose dry powder inha-
ler (SDDPI) under double-blind conditions. Subjects ran-
domized to the placebo/moxifloxacin arm received
double-blind placebo via SDDPI for 14 days, with a single
open-label oral dose of moxifloxacin 400 mg on Day 14.
Concomitant treatment
Except for paracetamol and any medication needed to
treat adverse events (AEs), no medication other than
study drug was allowed from the start of screening until
the completion of all evaluations in the study.
Assessments
ECG profiling
Serial 12-lead surface ECGs were obtained using digital
ECG equipment (ELI 250™, Mortara Instrument Inc.,
Milwaukee, WI, USA) at baseline (Day -1) at the equiva-
lent of predose and 1 and 12 h post-dose. During the
treatment period, three ECG recordings were collected
at each of the following times on Days 1 and 14: at pre-
dose, and at 10, 20, and 40 min, and 1, 2, 3, 4, 6, 12,
and 24 h post-dose. All ECGs were recorded after sub-
jects had been resting in the supine position for at least
15 min (or 8 min for the 10 min post-dose reading).
The digital ECG recordings were transmitted electroni-
cally to a central facility for blinded manual interpreta-
tion and analysis. All ECG readers were blinded to all
elements of the study, including treatment assignments
and subject demographics.
Pharmacokinetic assessments
Pharmacokinetic samples were taken to determine the
relationship between indacaterol concentration and QTc
interval. Serial blood samples were collected on Days 1
and 14 at predose and at 10, 20, and 40 min, and 1, 2,
3, 4, 6, 12, and 24 h post-dose. Serum was obtained
from all blood samples by centrifugation and kept fro-
zen at ≤ -20°C until analysis. Serum indacaterol was
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measured using a liquid chromatography/mass spectro-
metry/mass spectrometry method; the lower limit of
quantification for indacaterol was 10 pg/mL. The maxi-
mum (peak) serum concentration (Cmax) and the area
under the concentration-time curve from 0 to 24 h
post-dose (AUC0-24h) were determined on Days 1 and
14, and were presented as the mean and standard devia-
tion (SD).
Safety assessments
Safety assessments included recording of AEs and ser-
ious adverse events (SAEs) with severity and relationship
to study drug; collection of clinical laboratory data for
urinalysis, hematology, and blood chemistry (including
serum potassium and plasma glucose); and regular
assessments of vital signs, ECGs, and body weight.
Sample size calculation and statistical analysis
The primary endpoint for the study was the QTcF inter-
val (QT interval corrected for heart rate using Frideri-
cia’s formula, QT/RR0.33). This formula is recommended
for investigating the effect of drugs that may affect pulse
rate [9,12,13]. For each of three ECGs taken at each
nominal time, the QT and RR intervals were measured
from three consecutive QRST complexes from lead II.
The mean of the triplicate ECG value was then
calculated.
The primary objective of this study was to compare
indacaterol 150, 300 and 600 μg with placebo in terms
of the change in QTcF interval from baseline at each of
the 10 post-dose time points on Day 14. Baseline QTcF
interval was defined as the average of the pre-treatment
measurements taken on Day -1 and the predose mea-
surement on Day 1.
The sample size calculation was based on a residual
standard deviation of 10.95 ms for the primary endpoint
observed in a previous indacaterol study (data on file).
Assuming a 5 ms difference between indacaterol 150 μg
or 300 μg and placebo in terms of change from baseline
in QTcF interval at the first four post-dose assessment
time points on Day 14 and no difference at the next six
time points, it was calculated that a sample size of 102
subjects was required in each treatment group to
demonstrate that all upper one-sided 95% confidence
intervals were below 10 ms.
For the comparison of indacaterol 600 μg versus pla-
cebo, 52 subjects in each treatment arm were required
in order to show that all upper one-sided 95% confi-
dence intervals were <20 ms. This calculation assumed
an estimated difference of 13 ms between indacaterol
600 μg and placebo in terms of change from baseline in
QTcF interval at the first four assessment time points
and no difference between the treatments at the next six
time points.
For the comparison between moxifloxacin and pla-
cebo, 26 subjects per treatment arm were required to
conclude an assay sensitivity with 95% power based on
the assumption that the difference between moxifloxacin
and placebo for QTcF interval change from baseline was
at least 5 ms and that this difference could be detected
at least at 4 of the 10 post-dose assessment time points
on Day 14. Assuming a dropout rate of approximately
10%, the number of subjects to be randomized was 116,
116, 58, 116, and 29, for indacaterol 150, 300, 600 μg,
placebo, and placebo/moxifloxacin, respectively.
The absence of any meaningful effect of indacaterol
150 and 300 μg on cardiac repolarization was to be con-
cluded if the upper limit of all the 90% two-sided CIs
(equivalent to the upper limit of a 95% one-sided CI)
for the mean difference in the change in QTcF interval
from baseline between indacaterol (150 and 300 μg) and
placebo at each time point was <10 ms. A similar analy-
sis was performed for the supratherapeutic dose of inda-
caterol (600 μg) with the noninferiority margin set at a
prespecified constant of 20 ms for the upper limit of the
90% two-sided CIs. Confidence intervals were calculated
from pairwise determination of the pooled standard
error and the 10th and 90th percentiles of the t-distribu-
tion with appropriate degrees of freedom.
The average QTcF intervals (average of all scheduled
post-dose QTcF measurements up to 24 h post-dose)
and the peak QTcF intervals (highest QTcF interval
value observed over the period of 10 min to 24 h post-
dose) were calculated for all treatment groups on both
Days 1 and 14. In addition, the incidences of absolute
QTcF interval values >450, >480, and >500 ms were
summarized for each treatment group, as were the inci-
dences of changes from baseline in QTcF interval >30
and >60 ms.
Concentration-effect modeling
To determine the relationship between steady-state
serum concentration of indacaterol and QTcF interval,
change from baseline in QTcF interval was plotted
against the corresponding indacaterol concentration for
each time point on Day 14 (including all observations
under placebo and all indacaterol doses). A linear rela-
tionship between the two was established by plotting a
regression line, with the upper 95% simultaneous confi-
dence band also presented.
Results
Subject disposition, demographics, and baseline
characteristics
The study was conducted between April (first subject
enrolled) and August 2008 (last subject completed). A
total of 404 subjects were randomized, receiving indaca-
terol 150 μg (n = 108), indacaterol 300 μg (n = 108),
indacaterol 600 μg (n = 54), placebo (n = 107), or pla-
cebo/moxifloxacin (n = 27); 388 subjects (96%) com-
pleted the study (94%, 94%, 98%, 97% and 100% for
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indacaterol 150, 300 and 600 μg, placebo and placebo/
moxifloxacin, respectively). The most common reason
for premature discontinuation was loss to follow up
(n = 6) followed by withdrawal of consent (n = 4), AEs
(n = 3), protocol deviations (n = 2), and abnormal test
results (n = 1).
The treatment groups were well-balanced in terms of
demographic and baseline characteristics, except that
the proportion of Caucasian subjects (96%) was higher
in the placebo/moxifloxacin group as compared with the
other four treatment groups (85-89%) (Table 1).
QT interval data
Effect of indacaterol and moxifloxacin on QTcF interval
The mean differences in time-matched changes from
(time-averaged) baseline in QTcF interval between all
indacaterol doses and placebo on Day 14 were well
below 5 ms (the threshold of regulatory concern) at
each time point (Table 2, Figure 1), with no discernible
dose-relationship. The maximal time-matched mean dif-
ferences from placebo in QTcF change from baseline for
indacaterol 150 μg (2.66 ms) and 300 μg (2.98 ms) doses
were observed at 2 h post-dose (Table 2). The corre-
sponding maximal difference between indacaterol 600
μg and placebo (3.34 ms) was observed at 6 h post-dose
(Table 2). For all three indacaterol doses, the corre-
sponding upper bounds of the two-sided 90% CIs
(equivalent to the upper bound of a one-sided 95% CI)
excluded 10 ms indicating a negative thorough QT
study.
Moxifloxacin administration resulted in a clinically
significant increase in QTcF, thereby establishing the
assay sensitivity of the trial. The largest mean difference
between placebo/moxifloxacin and placebo alone (13.90
ms) was observed at 2 h post-dose; the corresponding
upper bound of the two-sided 90% CI (17.22 ms)
exceeded the regulatory threshold at this timepoint and
at several other timepoints (Table 2, Figure 1) [9].
Table 3 shows the treatment comparisons between the
indacaterol doses and placebo with respect to average
and peak QTcF on Days 1 and 14. As with the primary
analysis, all mean values were below 5 ms, with the
upper bound of all 90% confidence intervals being
below 10 ms.
Table 1 Demographic and baseline characteristics of the study participants
Demographic parameter Indacaterol Placebo Placebo/moxifloxacin
150 μg 300 μg 600 μg
N = 108 N = 108 N = 54 N = 107 N = 27
Male, n (%) 76 (70.4) 75 (69.4) 37 (68.5) 76 (71.0) 18 (66.7)
Female, n (%) 32 (29.6) 33 (30.6) 17 (31.5) 31 (29.0) 9 (33.3)
Age (yrs), mean (SD) 37.4 (9.98) 39.0 (10.28) 39.1 (9.65) 38.5 (10.46) 39.0 (10.58)
Body mass index (kg/m2), mean (SD) 26.6 (2.85) 26.9 (2.78) 26.7 (2.43) 26.8 (2.66) 26.0 (3.17)
Weight (kg), mean (SD) 76.6 (11.97) 77.4 (11.50) 76.4 (10.26) 78.0 (11.64) 73.2 (13.50)
Race
○Caucasian (%) 96 (88.9) 95 (88.0) 46 (85.2) 95 (88.8) 26 (96.3)
○Black (%) 11 (10.2) 13 (12.0) 8 (14.8) 12 (11.2) 1 (3.7)
○Other (%) 1 (0.9) 0 0 0 0
Table 2 Difference versus placebo in the change in QTcF interval from baseline on Day 14
Time post- dose Indacaterol Placebo/moxifloxacin vs placebo
150 μg vs placebo 300 μg vs placebo 600 μg vs placebo
Mean (90% confidence intervals), in ms
10 min 1.62 (-0.34, 3.57) 1.26 (-0.64, 3.16) 1.56 (-0.83, 3.94) 1.84 (-1.32, 5.01)
20 min 2.23 (0.34, 4.12) 2.24 (0.45, 4.03) 2.84 (0.72, 4.95) 3.74 (0.97, 6.51)
40 min 2.12 (0.21, 4.03) 1.54 (-0.41, 3.49) 1.40 (-0.96, 3.76) 8.25 (5.04, 11.47)
1 h 0.89 (-1.12, 2.89) 1.05 (-0.99, 3.09) 0.70 (-1.72, 3.12) 10.76 (7.60, 13.93)
2 h 2.66 (0.55, 4.77) 2.98 (1.02, 4.93) 2.18 (-0.25, 4.61) 13.90 (10.58, 17.22)
3 h 0.48 (-1.53, 2.50) 1.06 (-0.91, 3.03) 2.14 (-0.19, 4.48) 11.12 (8.08, 14.15)
4 h 0.36 (-1.82, 2.53) 0.29 (-1.76, 2.33) 1.17 (-1.26, 3.59) 11.91 (8.57, 15.24)
6 h 0.46 (-1.70, 2.62) 1.21 (-0.64, 3.05) 3.34 (0.86, 5.82) 9.25 (5.93, 12.57)
12 h 0.44 (-1.69, 2.57) -1.24 (-3.26, 0.79) -1.62 (-4.23, 0.98) 4.24 (0.82, 7.67)
24 h 1.88 (0.12, 3.64) 0.67 (-1.15, 2.49) -0.08 (-2.27, 2.11) 7.77 (4.73, 10.82)
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Categorical analysis
Two subjects, one each from the indacaterol 150 μg (20
min post-dose on Day 14) and 300 μg (10 min post-dose
on Day 1) dose groups, demonstrated QTcF interval values
exceeding 450 ms; no values exceeded 480 ms. There were
no QTcF changes from baseline >60 ms. A total of ten
changes >30 ms were recorded: five with indacaterol 150
μg (one subject had three values and two others had one
value >30 ms each); three with placebo (three subjects
with one value >30 ms each); and two with placebo/moxi-
floxacin (one subject with two values >30 ms).
Pharmacokinetics
Indacaterol was absorbed rapidly following inhalation,
with a median time to reach peak serum concentrations
on Days 1 and 14 of 15 min post-dose. After 14 days of
once-daily dosing, indacaterol appeared to achieve
steady state. At steady state (i.e., on Day 14), Cmax and
AUC0-24h increased proportionally over the entire dose
range (150-600 μg) (Table 4).
Concentration-QTcF interval relationship
A scatter plot (Figure 2) was used to assess the relation-
ship between Day 14 indacaterol serum concentration
and change in QTcF interval from baseline following
multiple dosing with indacaterol 150, 300, and 600 μg.
At all concentrations up to 3000 pg/mL, the 95% confi-
dence band of the regression line was below the line for
10 ms QTcF change from baseline. These results sup-
port the QTcF interval analysis and indicate that prolon-
gation of QTcF interval above 10 ms is not expected at
doses of indacaterol resulting in steady-state Cmax values
up to 3000 pg/mL.
Safety results
The overall incidence of AEs was 47.2% (51/108), 54.6%
(59/108), and 61.1% (33/54) with indacaterol 150 μg,
300 μg, and 600 μg, respectively, as compared with
47.7% (51/107) with placebo, and 51.9% (14/27) with
placebo/moxifloxacin. The most common AE was con-
tact dermatitis (indacaterol 150 μg: n = 31 [28.7%]; inda-
caterol 300 μg: n = 36 [33.3%]; indacaterol 600 μg: n =
21 [38.9%]; placebo: n = 30 [28.0%]; placebo/moxifloxa-
cin: n = 6 [22.2%]) attributed to the repeated application
and removal of adhesive ECG electrodes. AEs were
mostly mild in severity and in most cases were not sus-
pected to be study drug related. Two subjects experi-
enced SAEs, one receiving indacaterol 300 μg (chest
pain) and one receiving placebo (acute depression).
Neither event was suspected to be study drug related,
although both subjects were withdrawn from the study.
No death was reported during the study. There were no
clinically notable serum potassium or blood glucose
values or any abnormalities pertaining to heart rate or
other vital signs in any group.
Discussion
In this study, indacaterol 150 μg, 300 μg, and 600 μg,
administered once-daily for 14 days resulted in a maxi-
mum mean prolongation in QTcF of less than 5 ms ver-
sus placebo, with the upper limit of all two-sided 90%
CIs being below 10 ms. Therefore, according to the ICH
E14 guidelines [9], the present thorough QT study can
be deemed negative, indicating that indacaterol has no
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Figure 1 Difference from placebo in mean change from
baseline in QTcF on Day 14. Data presented are mean and 90%
confidence interval. Dotted horizontal line corresponds to the 10 ms
threshold.
Table 3 Difference between indacaterol and placebo for average and peak QTcF on Days 1 and 14
Indacaterol 150 μg vs placebo Indacaterol 300 μg vs placebo Indacaterol 600 μg vs placebo
Least squares mean (90% confidence intervals)
Day 1 Day 14 Day 1 Day 14 Day 1 Day 14
Average QTcF (ms) 0.66 1.32 2.09 1.04 3.71 1.00
(-0.22, 1.53) (-0.20, 2.84) (1.21, 2.96) (-0.48, 2.56) (2.64, 4.79) (-0.85, 2.84)
Peak QTcF (ms) -0.21 1.23 2.04 0.38 3.57 0.45
(-1.40, 0.97) (-0.56, 3.02) (0.86, 3.22) (-1.41, 2.17) (2.12, 5.02) (-1.72, 2.62)
Analysis of covariance including baseline QTcF as a covariate and treatment as a fixed effect
Average QTcF is the average of all scheduled post dose QTcF measurements between dosing and 24 h post-dose
Peak QTcF is the maximum QTcF of all scheduled post-dose QTcF measurements between dosing and 24 h post-dose
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In terms of dose-effect relationship, the highest dose
of indacaterol (600 μg) resulted in the largest QT inter-
val prolongation on Day 14 (3.34 ms at 6 h post-dose);
however, the respective 90% CIs for all indacaterol doses
largely overlapped with one another suggesting the
absence of any dose-QTcF relationship. The lack of
dose-dependency in the investigated dose range further
supported by the mean QTcF changes from baseline on
Day 14, which showed similar, small (<5 ms) and transi-
ent increases in QTcF interval in each indacaterol dose
group compared with placebo. Further, on Day 14 there
were only marginal and non-significant changes in aver-
age and peak QTcF intervals with all three doses of
indacaterol, with the concentration-QTcF interval analy-
sis indicating that a prolongation above 10 ms is not
expected at doses of indacaterol resulting in steady-state
Cmax values up to 3000 pg/mL. This is particularly rele-
vant, given that according to the prescribing information
for formoterol and salmeterol, at high doses these other
b2-agonists are associated with QT interval prolonga-
tion. Since this study did not include any other LABAs,
one cannot draw any direct conclusions from the results
about the relative cardiovascular safety of indacaterol,
salmeterol and formoterol. Such a comparison is of
interest, given that these three LABAs have different
intrinsic efficacies [14]. However a 12-month study in
which patients with COPD were randomized to receive
indacaterol 300 μg or 600 μg, formoterol or placebo,
showed that all four treatments had similar good overall
safety profiles [8]. Furthermore, given that the current
study recruited healthy volunteers (in accordance with
ICH E14 guidelines), the earlier 12-month study is use-
ful in that it also provides evidence of cardiovascular
safety in patients with COPD and a range of comorbid
conditions (including hypertension and Type II diabetes
mellitus). In addition, in a recent post-hoc analysis of
the indacaterol trial database, indacaterol did not
increase the risk of cerebrovascular or cardiovascular
adverse events compared with placebo, formoterol or
salmeterol [15].
In accordance with the ICH E14 guidelines, moxiflox-
acin was included in the study as a positive control, and
administration of a single 400 mg dose resulted in a
clinically significant increase in QTcF interval, thereby
establishing the assay sensitivity of the trial. QTc inter-
val prolongation with moxifloxacin in this trial was simi-
lar to that reported previously [11].
The indacaterol doses administered in this study (150
μg, 300 μg, and 600 μg) were selected based on a dose
finding study which used an adaptive seamless study
design [16], and which identified the 150 and 300 μg
doses for further development. These two doses were
subsequently approved in a number of countries, includ-
ing throughout the European Union, for maintenance
treatment of COPD. Previous studies have demonstrated
that patient age, weight and ethnicity have no clinically
relevant effect on indacaterol pharmacokinetics (Cmax
and AUC; data on file). Further, metabolic drug interac-
tions raise the systemic exposure of indacaterol by a
maximum of two-fold (data on file). In this context, the
absence of prolongation of QTcF above 10 ms with the
600 μg dose (i.e., two- to four-fold higher than the
approved EU doses) is a relevant finding for the safety
profile of indacaterol.
Notably, in the current study no change from baseline
in QTcF interval of >60 ms was observed with any of
the indacaterol doses, and nor were any QTcF interval
values >480 ms observed. These results also demon-
strated that indacaterol did not prolong QTc interval
and further suggests that there were no outliers in
terms of QTc interval prolongation. Indeed in a pre-
vious study in patients with mild or moderate COPD,
Table 4 Cmax and AUC0-24h of indacaterol after once-daily
inhalation on Days 1 and 14
Dose (μg) Cmax (pg/mL) AUC0-24h (pg·h/mL)
mean ± SD mean ± SD
Day 1 150 252.9 ± 120.84 1202.0 ± 553.93
300 537.2 ± 224.23 2639.4 ± 862.08
600 1043.8 ± 285.47 5279.1 ± 1155.28
Day 14 150 438.6 ± 196.38 3881.7 ± 1545.39
300 858.6 ± 264.16 8137.0 ± 2388.41
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Figure 2 Relationship between indacaterol concentration and
QTcF change from baseline following 14-day treatment with
indacaterol. The solid diagonal line represents the estimated
regression of concentration against change from baseline in QTcF
interval; the dotted diagonal line represents the corresponding 95%
upper confidence band. The horizontal lines show 0 and 10 ms
change from baseline in QTcF interval; the vertical lines are the
geometric mean and 90% confidence limits for Cmax in the
indacaterol 600 μg group.
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even at single doses as high as 3000 μg indacaterol had
minimal effects on the QTc interval [17].
Conclusion
The results of this thorough QT study carried out in
over 400 healthy subjects indicate that indacaterol, at
doses up to 600 μg once daily (2-4 times the therapeutic
dose) does not have any clinically relevant effect on the
QT interval.
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